Epigenetic diet: Impact on the epigenome and cancer

Epigenomics

Volumn 3, Issue 4, 2011, Pages 503-518

  Hardy, Tabitha M ^a   Tollefsbol, Trygve O ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

acetylation; cancer; dietary; epigenetic; methylation; nutrigenomics

Indexed keywords

BENZYL ISOTHIOCYANATE; CHOLINE; CURCUMIN; CYSTEINE; EPIGALLOCATECHIN GALLATE; FOLIC ACID; GARLIC EXTRACT; GENISTEIN; ISOFLAVONE; ISOTHIOCYANIC ACID DERIVATIVE; METHIONINE; PHENETHYL ISOTHIOCYANATE; PLANT MEDICINAL PRODUCT; POLYPHENOL; RESVERATROL; SELENATE; SELENITE; SELENOCYSTEINE;

CANCER CHEMOTHERAPY; CANCER PREVENTION; DIETARY INTAKE; EPIGENETICS; GARLIC; GENOME; HUMAN; NEOPLASM; PRIORITY JOURNAL; REVIEW; TEA;

ANTICARCINOGENIC AGENTS; CATECHIN; CURCUMIN; DIET; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; GENISTEIN; HISTONES; HUMANS; ISOTHIOCYANATES; MICRORNAS; NEOPLASMS; POLYPHENOLS; STILBENES; TEA;

EID: 80052009897     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.11.71     Document Type: Review

References (220)

1. Knekt P, Järvinen R, Seppänen R et al. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am. J. Epidemiol. 146(3), 223-230 (1997).
2. Howells LM, Moiseeva EP, Neal CP et al. Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals. Acta Pharmacol. Sin. 28(9), 1274-1304 (2007).
3. Fowke JH. Head and neck cancer. A case for inhibition by isothiocyanates and indoles from cruciferous vegetables. Eur. J. Cancer Prev. 16(4), 348-356 (2007).
4. De Kok T, Van Breda S, Manson M. Mechanisms of combined action of different chemopreventive dietary compounds. Eur. J. Nutr. 47, 51-59 (2008).
5. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 269(2), 199-225 (2008).
6. Ravindran J, Prasad S, Aggarwal B. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J. 11(3), 495-510 (2009).
7. Ho E, Clarke JD, Dashwood RH. Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention. J. Nutr. 139(12), 2393-2396 (2009).
8. Cheung KL, Khor TO, Huang M-T, Kong A-N. Differential in vivo mechanism of chemoprevention of tumor formation in azoxymethane/dextran sodium sulfate mice by PEITC and DBM. Carcinogenesis 31(5), 880-885 (2010).
9. Shu L, Cheung K-L, Khor T, Chen C, Kong A-N. Phytochemicals: cancer chemoprevention and suppression of tumor onset and metastasis. Cancer Metastasis Rev. 29(3), 483-502 (2010).
10. Waddington CH. The epigenotype. Endeavour 1, 18-20 (1942).
11. Holliday R. Mechanisms for the control of gene activity during development. Biol. Rev. Camb. Philos. Soc. 65(4), 431-471 (1990).
12. Herceg Z. Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis 22(2), 91-103 (2007).
13. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 16(1), 6-21 (2002).
14. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3(6), 415-428 (2002).
15. Altaf M, Saksouk N, Côté J. Histone modifications in response to DNA damage. Mutat. Res. 618(1-2), 81-90 (2007).
16. Meeran S, Ahmed A, Tollefsbol T. Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin. Epigenetics 1(3), 101-116 (2010).
17. Tate PH, Bird AP. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr. Opin. Genet. Dev. 3(2), 226-231 (1993).
18. Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 66(5), 2794-2800 (2006).
19. Grafodatskaya D, Chung B, Szatmari P, Weksberg R. Autism spectrum disorders and epigenetics. J. Am. Acad. Child Adolesc. Psychiatry 49(8), 794-809 (2010).
20. Milagro FI, Campión J, Cordero P et al. A dual epigenomic approach for the search of obesity biomarkers: DNA methylation in relation to diet-induced weight loss. FASEB J. 25(4), 1378-1389 (2011).
21. Maier S, Olek A. Diabetes: a candidate disease for efficient DNA methylation profiling. J. Nutr. 132(8), 2440S-2443S (2002).
22. Chowdhury S, Erickson SW, Macleod SL et al. Maternal genome-wide DNA methylation patterns and congenital heart defects. PLoS ONE 6(1), e16506 (2011).
23. Nephew KP, Huang TH-M. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett. 190(2), 125-133 (2003).
24. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301(5895), 89-92 (1983).
25. Irizarry RA, Ladd-Acosta C, Wen B et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 41(2), 178-186 (2009).
26. Doi A, Park I-H, Wen B et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet. 41(12), 1350-1353 (2009).
27. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 7(1), 21-33 (2006).
28. Hassan YI, Zempleni J. Epigenetic regulation of chromatin structure and gene function by biotin. J. Nutr. 136(7), 1763-1765 (2006).
29. Choudhuri S, Cui Y, Klaassen CD. Molecular targets of epigenetic regulation and effectors of environmental influences. Toxicol. Appl. Pharmacol. 245(3), 378-393 (2010).
30. Mottet D, Castronovo V. Histone deacetylases: target enzymes for cancer therapy. Clin. Exp. Metastasis 25(2), 183-189 (2008).
31. Lafon-Hughes L, Di Tomaso MV, Méndez-Acuña L, Martínez-López W. Chromatin-remodelling mechanisms in cancer. Mutat. Res. 658(3), 191-214 (2008).
32. Montgomery MK, Xu S, Fire A. RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc. Natl Acad. Sci. USA 95(26), 15502-15507 (1998).
33. Volpe TA, Kidner C, Hall IM, Teng G, Grewal SIS, Martienssen RA. Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi. Science 297(5588), 1833-1837 (2002).
34. Panning B, Jaenisch R. RNA and the epigenetic regulation of X chromosome inactivation. Cell 93(3), 305-308 (1998).
35. Zilberman D, Cao X, Jacobsen SE. ARGONAUTE4 control of locus-specific siRNA accumulation and DNA and histone methylation. Science 299(5607), 716-719 (2003).
36. Tufarelli C, Stanley JA, Garrick D et al. Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease. Nat. Genet. 34(2), 157-165 (2003).
37. Wang Y-H, Liu S, Zhang G et al. Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res. 7(2), R220-R228 (2005).
38. Lakka SS, Gondi CS, Dinh DH et al. Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. J. Biol. Chem. 280(23), 21882-21892 (2005).
39. Fleming JB, Shen G-L, Holloway SE, Davis M, Brekken RA. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol. Cancer Res. 3(7), 413-423 (2005).
40. Liang X, Yang X, Tang Y et al. RNAi-mediated downregulation of urokinase plasminogen activator receptor inhibits proliferation, adhesion, migration and invasion in oral cancer cells. Oral Oncol. 44(12), 1172-1180 (2008).
41. Yavari K, Taghikhani M, Ghannadi Maragheh M, Mesbah-Namin S, Babaei M. Downregulation of IGF-IR expression by RNAi inhibits proliferation and enhances chemosensitization of human colon cancer cells. Int. J. Colorectal Dis. 25(1), 9-16 (2010).
42. Lujambio A, Portela A, Liz J et al. CpG island hypermethylation- associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene 29(48), 6390-6401 (2010).
43. Guil S, Esteller M. DNA methylomes, histone codes and miRNAs: Tying it all together. Int. J. Biochem. Cell Biol. 41(1), 87-95 (2009).
44. Ducasse M, Brown M. Epigenetic aberrations and cancer. Mol. Cancer 5(1), 60 (2006).
45. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990), 457-463 (2004).
46. Martínez MA, Gutiérrez A, Armand-Ugón M et al. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 16(18), 2385-2390 (2002).
47. Jones PA, Baylin SB. The epigenomics of cancer. Cell 128(4), 683-692 (2007).
48. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 5(1), 37-50 (2006).
49. Schuebel KE, Chen W, Cope L et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet. 3(9), e157 (2007).
50. Cairns P. Gene methylation and early detection of genitourinary cancer: the road ahead. Nat. Rev. Cancer 7(7), 531-543 (2007).
51. Cox PM, Goding CR. Transcription and cancer. Br. J. Cancer 63(5), 651-662 (1991).
52. Taby R, Issa J-PJ. Cancer epigenetics.CA Cancer J. Clin. 60(6), 376-392 (2010).
53. Issa J-P. Cancer prevention: epigenetics steps up to the plate. Cancer Prev. Res. 1(4), 219-222 (2008).
54. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59(1), 67-70 (1999).
55. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358(11), 1148-1159 (2008).
56. Link A, Balaguer F, Goel A. Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem. Pharmacol. 80(12), 1771-1792 (2010).
57. Landis-Piwowar KR, Milacic V, Dou QP. Relationship between the methylation status of dietary flavonoids and their growth-inhibitory and apoptosis-inducing activities in human cancer cells. J. Cell. Biochem. 105(2), 514-523 (2008).
58. Li Y, Tollefsbol TO. p16INK4a suppression by glucose restriction contributes to human cellular lifespan extension through SIRT1- mediated epigenetic and genetic mechanisms. PLoS ONE 6(2), e17421 (2011).
59. Meeran SM, Patel SN, Tollefsbol TO. Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS ONE 5(7), e11457 (2010).
60. Paluszczak J, Krajka-Kuzniak V, Baer- Dubowska W. The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells. Toxicol. Lett. 192(2), 119-125 (2010).
61. Lee KW, Lee HJ, Lee CY. Vitamins, phytochemicals, diets, and their implementation in cancer chemoprevention. Crit. Rev. Food Sci. Nutr. 44(6), 437-452 (2004).
62. Singh KP, Dumond JW. Genetic and epigenetic changes induced by chronic low dose exposure to arsenic of mouse testicular Leydig cells. Int. J. Oncol. 30(1), 253-260 (2007).
63. Xie Y, Liu J, Benbrahim-Tallaa L et al. Aberrant DNA methylation and gene expression in livers of newborn mice transplacentally exposed to a hepatocarcinogenic dose of inorganic arsenic. Toxicology 236(1-2), 7-15 (2007).
64. Bertram C, Khan O, Ohri S, Phillips DI, Matthews SG, Hanson MA. Transgenerational effects of prenatal nutrient restriction on cardiovascular and hypothalamic-pituitary-adrenal function. J. Physiol. 586(8), 2217-2229 (2008).
65. Novikova SI, He F, Bai J, Cutrufello NJ, Lidow MS, Undieh AS. Maternal cocaine administration in mice alters DNA methylation and gene expression in hippocampal neurons of neonatal and prepubertal offspring. PLoS ONE 3(4), e1919 (2008).
66. Andersen HR, Schmidt IM, Grandjean P et al. Impaired reproductive development in sons of women occupationally exposed to pesticides during pregnancy. Environ. Health Perspect. 116(4), 566-572 (2008).
67. Heijmans BT, Tobi EW, Stein AD et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc. Natl Acad. Sci. 105(44), 17046-17049 (2008).
68. Skinner MK, Guerrero-Bosagna C. Environmental signals and transgenerational epigenetics. Epigenomics 1(1), 111-117 (2009).
69. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 33, 245-254 (2003).
70. Poirier LA. Methyl group deficiency in hepatocarcinogenesis. Drug Metab. Rev. 26(1-2), 185-199 (1994).
71. Pogribny IP, Ross SA, Wise C et al. Irreversible global DNA hypomethylation as a key step in hepatocarcinogenesis induced by dietary methyl deficiency. Mutat. Res. 593(1-2), 80-87 (2006).
72. Bravo L. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr. Rev. 56(11), 317-333 (1998).
73. Harborne J. Methods in plant biochemistry. In: Plant Phenolics. Academic Press, London, UK (1989).
74. Shukla Y, Singh R. Resveratrol and cellular mechanisms of cancer prevention. Ann. NY Acad. Sci. 1215(1), 1-8 (2011).
75. Cui X, Jin Y, Hofseth AB et al. Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev. Res. 3(4), 549-559 (2010).
76. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 71(10), 1397-1421 (2006).
77. Fang M, Chen D, Yang CS. Dietary polyphenols may affect DNA methylation. J. Nutr. 137(1), 223S-228S (2007).
78. Lee WJ, Shim J-Y, Zhu BT. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol. Pharmacol. 68(4), 1018-1030 (2005).
79. Shen FM, Chen HW. Element composition of tea leaves and tea infusions and its impact on health.Bull. of Environ. Contam. Toxicol. 80(3), 300-304 (2008).
80. Fujihara T, Nakagawa-Izumi A, Ozawa T, Numata O. High-molecular-weight polyphenols from oolong tea and black tea: purification, some properties, and role in increasing mitochondrial membrane potential. Biosci. Biotechnol. Biochem. 71(3), 711-719 (2007).
81. Graham HN. Green tea composition, consumption, and polyphenol chemistry. Prev. Med. 21(3), 334-350 (1992).
82. Lin J-K, Liang Y-C, Lin-Shiau S-Y. Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade. Biochem. Pharmacol. 58(6), 911-915 (1999).
83. Chuang JC, Yoo CB, Kwan JM et al. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. Mol. Cancer Ther. 4(10), 1515-1520 (2005).
84. Shanmugam MK, Kannaiyan R, Sethi G. Targeting cell signaling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer. Nutr. Cancer 63(2), 161-173 (2011).
85. Chen P-N, Chu S-C, Kuo W-H, Chou M-Y, Lin J-K, Hsieh Y-S. Epigallocatechin-3 gallate inhibits invasion, epithelial-mesenchymal transition, and tumor growth in oral cancer cells. J. Agric. Food Chem. 59(8), 3836-3844 (2011).
86. Tu S-H, Ku C-Y, Ho C-T et al. Tea polyphenol (-)-epigallocatechin-3- gallate inhibits nicotine- and estrogen-induced a9-nicotinic acetylcholine receptor upregulation in human breast cancer cells. Mol. Nutr. Food Res. 55(3), 455-466 (2011).
87. Kürbitz C, Heise D, Redmer T et al. Epicatechin gallate and catechin gallate are superior to epigallocatechin gallate in growth suppression and anti-inflammatory activities in pancreatic tumor cells. Cancer Sci. 102(4), 728-734 (2011).
88. Kim JW, Amin AR, Shin DM. Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prev. Res. 3(8), 900-909 (2010).
89. Yang C, Lambert J, Sang S. Antioxidative and anti-carcinogenic activities of tea polyphenols. Arch. Toxicol. 83(1), 11-21 (2009).
90. Li Y, Tollefsbol TO. Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr. Med. Chem. 17, 2141-2151 (2010).
91. Farabegoli F, Papi A, Bartolini G, Ostan R, Orlandi M. (-)-epigallocatechin-3-gallate downregulates P-gP and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine 17, 356-362 (2010).
92. Balasubramanian S, Adhikary G, Eckert RL. The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3- gallate-dependent suppression of skin cancer cell survival. Carcinogenesis 31(3), 496-503 (2010).
93. Berletch JB, Liu C, Love WK, Andrews LG, Katiyar SK, Tollefsbol TO. Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG. J. Cell. Biochem. 103(2), 509-519 (2008).
94. Lee AH, Fraser ML, Meng X, Binns CW. Protective effects of green tea against prostate cancer. Expert Rev. Anticancer Ther. 6(4), 507-513 (2006).
95. Fang MZ, Wang Y, Ai N et al. Tea polyphenol (-)-epigallocatechin-3- gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 63(22), 7563-7570 (2003).
96. Nandakumar V, Vaid M, Katiyar SK. (-)-epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. Carcinogenesis 32(4), 537-544 (2011).
97. Li Y, Yuan Y-Y, Meeran S, Tollefsbol T. Synergistic epigenetic reactivation of estrogen receptor-a (ERa) by combined green tea polyphenol and histone deacetylase inhibitor in ERa-negative breast cancer cells. Mol. Cancer 9(1), 274 (2010).
98. Gao Z, Xu Z, Hung M-S et al. Promoter demethylation of WIF-1 by epigallocatechin- 3-gallate in lung cancer cells. Anticancer Res. 29(6), 2025-2030 (2009).
99. Kato K, Long NK, Makita H et al. Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral squamous cell carcinoma cells. Br. J. Cancer 99(4), 647-654 (2008).
100. Pandey M, Shukla S, Gupta S. Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells. Int. J. Cancer 126(11), 2520-2533 (2010).
101. Choi K-C, Jung MG, Lee Y-H et al. Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Res. 69(2), 583-592 (2009).
102. Tsang WP, Kwok TT. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J. Nutr. Biochem. 21(2), 140-146 (2010).
103. Tran P, Kim S-A, Choi H, Yoon J-H, Ahn S-G. Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo. BMC Cancer 10(1), 276 (2010).
104. Sagara Y, Miyata Y, Nomata K, Hayashi T, Kanetake H. Green tea polyphenol suppresses tumor invasion and angiogenesis in N-butyl-(-4-hydroxybutyl) nitrosamine-induced bladder cancer. Cancer Epidemiol. 34(3), 350-354 (2010).
105. Zhang D, Al-Hendy M, Richard-Davis G et al. Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am. J. Obs. Gynecol. 202(3), 289 e1-e9 (2010).
106. Lam WH, Kazi A, Kuhn DJ et al. A potential prodrug for a green tea polyphenol proteasome inhibitor: evaluation of the peracetate ester of (-)-epigallocatechin gallate [(-)-EGCG]. Bioorganic Med. Chem. 12(21), 5587-5593 (2004).
107. Meeran SM, Patel SN, Chan T-H, Tollefsbol TO. A novel prodrug of epigallocatechin-3-gallate: Differential epigenetic hTERT repression in human breast cancer cells. Cancer Prev. Res. doi: 10.1158/1940-6207.CAPR-11-0009 (2011) (Epub ahead of print).
108. Landis-Piwowar KR, Huo C, Chen D et al. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res. 67(9), 4303-4310 (2007).
109. Das D, Mukherjee S, Ray D. Resveratrol and red wine, healthy heart and longevity. Heart Fail. Rev. 15(5), 467-477 (2010).
110. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch. Biochem. Biophys. 486(2), 95-102 (2009).
111. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug. Discov. 5(6), 493-506 (2006).
112. Bishayee A, Waghray A, Barnes K et al. Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharmaceut. Res. 27(6), 1080-1091 (2010).
113. Bishayee A, Politis T, Darvesh AS. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat. Rev. 36(1), 43-53 (2010).
114. Kraft TE, Parisotto D, Schempp C, Efferth T. Fighting cancer with red wine? Molecular mechanisms of resveratrol. Crit. Rev. Food Sci. Nutr. 49(9), 782-799 (2009).
115. Mao Q-Q, Bai Y, Lin Y-W et al. Resveratrol confers resistance against taxol via induction of cell cycle arrest in human cancer cell lines. Mol. Nutr. Food Res. 54(11), 1574-1584 (2010).
116. Vanamala J, Reddivari L, Radhakrishnan S, Tarver C. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer 10(1), 238 (2010).
117. Liu P-L, Tsai J-R, Charles AL et al. Resveratrol inhibits human lung adenocarcinoma cell metastasis by suppressing heme oxygenase 1-mediated nuclear factor-kB pathway and subsequently downregulating expression of matrix metalloproteinases. Mol. Nutr. Food Res. 54(S2), S196-S204 (2010).
118. Wu H, Liang X, Fang Y, Qin X, Zhang Y, Liu J. Resveratrol inhibits hypoxia-induced metastasis potential enhancement by restricting hypoxia-induced factor-1[a] expression in colon carcinoma cells. Biomed. Pharmacother. 62(9), 613-621 (2008).
119. Weng YL, Liao HF, Li AF, Chang JC, Chiou RY. Oral administration of resveratrol in suppression of pulmonary metastasis of BALB/c mice challenged with CT26 colorectal adenocarcinoma cells. Mol. Nutr. Food Res. 54(2), 259-267 (2010).
120. Jang M, Cai L, Udeani GO et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275(5297), 218-220 (1997).
121. Papoutsis AJ, Lamore SD, Wondrak GT, Selmin OI, Romagnolo DF. Resveratrol prevents epigenetic silencing of BRCA-1 by the aromatic hydrocarbon receptor in human breast cancer cells. J. Nutr. 140(9), 1607-1614 (2010).
122. Stefanska B, Rudnicka K, Bednarek A, Fabianowska-Majewska K. Hypomethylation and induction of retinoic acid receptor b 2 by concurrent action of adenosine analogues and natural compounds in breast cancer cells. Eur. J. Pharmacol. 638(1-3), 47-53 (2010).
123. Paluszczak J, Krajka-Kuzniak V, Malecka Z et al. Frequent gene hypermethylation in laryngeal cancer cell lines and the resistance to demethylation induction by plant polyphenols. Toxicol. In Vitro 25(1), 213-221 (2011).
124. Howitz KT, Bitterman KJ, Cohen HY et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425(6954), 191-196 (2003).
125. Hoshino I, Matsubara H. Recent advances in histone deacetylase targeted cancer therapy. Surgery Today 40(9), 809-815 (2010).
126. Pruitt K, Zinn RL, Ohm JE et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet. 2(3), e40 (2006).
127. Boily G, He XH, Pearce B, Jardine K, Mcburney MW. SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol. Oncogene 28(32), 2882-2893 (2009).
128. Feige JN, Lagouge M, Canto C et al. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 8(5), 347-358 (2008).
129. Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280(17), 17187-17195 (2005).
130. Wang R-H, Zheng Y, Kim H-S et al. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol. Cell 32(1), 11-20 (2008).
131. Stünkel W, Peh BK, Tan YC et al. Function of the SIRT1 protein deacetylase in cancer. Biotechnol. J. 2(11), 1360-1368 (2007).
132. Kai L, Samuel SK, Levenson AS. Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int. J. Cancer 126(7), 1538-1548 (2010).
133. Baur JA, Pearson KJ, Price NL et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444(7117), 337-342 (2006).
134. Haigis MC, Guarente LP. Mammalian sirtuins - emerging roles in physiology, aging, and calorie restriction. Genes Dev. 20(21), 2913-2921 (2006).
135. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. Life Sci. 78(18), 2081-2087 (2006).
136. Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr. Cancer 62(7), 919-930 (2010).
137. Liu Z, Xie Z, Jones W et al. Curcumin is a potent DNA hypomethylation agent. Bioorganic Med. Chem. Lett. 19(3), 706-709 (2009).
138. Kuck D, Singh N, Lyko F, Medina-Franco JL. Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorganic Med. Chem. 18(2), 822-829 (2010).
139. Fu S, Kurzrock R. Development of curcumin as an epigenetic agent. Cancer 116(20), 4670-4676 (2010).
140. Liu H-L, Chen Y, Cui G-H, Zhou J-F. Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation. Acta Pharmacol. Sin. 26(5), 603-609 (2005).
141. Valinluck V, Sowers LC. Inflammation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers. Cancer Res. 67(12), 5583-5586 (2007).
142. Kang S-K, Cha S-H, Jeon H-G. Curcumin-induced histone hypoacetylation enhances caspase-3-dependent glioma cell death and neurogenesis of neural progenitor cells. Stem Cells Dev. 15(2), 165-174 (2006).
143. Cui L, Miao J, Furuya T, Li X, Su X-Z, Cui L. PfGCN5-mediated histone H3 acetylation plays a key role in gene expression in Plasmodium falciparum. Eukaryotic Cell. 6(7), 1219-1227 (2007).
144. Pollack BP, Sapkota B, Boss JM. Ultraviolet radiation-induced transcription is associated with gene-specific histone acetylation. Photochem. Photobiol. 85(3), 652-662 (2009).
145. Sng JCG, Taniura H, Yoneda Y. Histone modifications in kainate-induced status epilepticus. Eur. J. Neurosci. 23(5), 1269-1282 (2006).
146. Chiu J, Khan ZA, Farhangkhoee H, Chakrabarti S. Curcumin prevents diabetes-associated abnormalities in the kidneys by inhibiting p300 and nuclear factor-kB. Nutrition 25(9), 964-972 (2009).
147. Tikoo K, Meena RL, Kabra DG, Gaikwad AB. Change in post-translational modifications of histone H3, heat-shock protein-27 and MAP kinase p38 expression by curcumin in streptozotocin-induced type I diabetic nephropathy. Br. J. Pharmacol. 153(6), 1225-1231 (2008).
148. Morimoto T, Sunagawa Y, Kawamura T et al. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J. Clin. Invest. 118(3), 868-878 (2008).
149. Lee Y-H, Hong SW, Jun W et al. Anti-histone acetyltransferase activity from allspice extracts inhibits androgen receptor-dependent prostate cancer cell growth. Biosci. Biotechnol. Biochem. 71(11), 2712-2719 (2007).
150. Reuter S, Eifes S, Dicato M, Aggarwal BB, Diederich M. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem. Pharmacol. 76(11), 1340-1351 (2008).
151. Marcu MG, Jung YJ, Lee S et al. Curcumin is an inhibitor of p300 histone acetyltransferase. Med. Chem. 2(2), 169-174 (2006).
152. Balasubramanyam K, Varier RA, Altaf M et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/ nonhistone proteins and histone acetyltransferase- dependent chromatin transcription. J. Biol. Chem. 279(49), 51163-51171 (2004).
153. Kutluay SB, Doroghazi J, Roemer ME, Triezenberg SJ. Curcumin inhibits herpes simplex virus immediate-early gene expression by a mechanism independent of p300/CBP histone acetyltransferase activity. Virology 373(2), 239-247 (2008).
154. Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol. Cancer Ther. 7(3), 464-473 (2008).
155. Ali S, Ahmad A, Banerjee S et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 70(9), 3606-3617 (2010).
156. Zhang F, Koh GY, Jeansonne DP et al. A novel solubility-enhanced curcumin formulation showing stability and maintenance of anticancer activity. J. Pharm. Sci. 100(7), 2778-2789 (2011).
157. Gupta NK, Dixit VK. Bioavailability enhancement of curcumin by complexation with phosphatidyl choline. J. Pharm. Sci. 100(5), 1987-1995 (2011).
158. Valls J, Millán S, Martí MP, Borràs E, Arola L. Advanced separation methods of food anthocyanins, isoflavones and flavanols. J. Chromatog. A 1216(43), 7143-7172 (2009).
159. Barnes S. Effect of genistein on in vitro and in vivo models of cancer. J. Nutr. 125(Suppl. 3), 777S-783S (1995).
160. Vardi A, Bosviel R, Rabiau N et al. Soy phytoestrogens modify DNA methylation of GSTP1, RASSF1A, EPH2 and BRCA1 promoter in prostate cancer cells. In vivo 24(4), 393-400 (2010).
161. Lattrich C, Lubig J, Springwald A, Goerse R, Ortmann O, Treeck O. Additive effects of trastuzumab and genistein on human breast cancer cells. Anti-Cancer Drugs 22(3), 253-261 (2011).
162. Fang MZ, Chen D, Sun Y, Jin Z, Christman K, Yang CS. Reversal of hypermethylation and reactivation of p16INK4a, RARb, and MGMT genes by genistein and other isoflavones from soy. Clin. Cancer Res. 11(19), 7033-7041 (2005).
163. Li Y, Liu L, Andrews LG, Tollefsbol TO. Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms. Int. J. Cancer 125(2), 286-296 (2009).
164. Majid S, Kikuno N, Nelles J et al. Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res. 68(8), 2736-2744 (2008).
165. Kikuno N, Shiina H, Urakami S et al. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int. J. Cancer 123(3), 552-560 (2008).
166. King-Batoon A, Leszczynska JM, Klein CB. Modulation of gene methylation by genistein or lycopene in breast cancer cells. Environ. Mol. Mutagen. 49(1), 36-45 (2008).
167. Majid S, Dar AA, Shahryari V et al. Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-cell translocation gene 3 in prostate cancer. Cancer 116(1), 66-76 (2010).
168. Majid S, Dar AA, Ahmad AE et al. BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis 30(4), 662-670 (2009).
169. Raynal NJ, Charbonneau M., Momparler LF, Momparler RL. Synergistic effect of 5-aza-2-deoxycytidine and genistein in combination against leukemia. Oncol. Res. 17, 223-230 (2008).
170. Li Y, Vandenboom TG, Kong D et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 69(16), 6704-6712 (2009).
171. Parker LP, Taylor DD, Kesterson J, Metzinger DS, Gercel-Taylor C. Modulation of microRNA associated with ovarian cancer cells by genistein. Eur. J. Gynaecol. Oncol. 30(6), 616-621 (2009).
172. Qin W, Zhu W, Shi H et al. Soy isoflavones have an antiestrogenic effect and alter mammary promoter hypermethylation in healthy premenopausal women. Nutri. Cancer 61, 238-244 (2009).
173. Cheung K, Kong A-N. Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention. AAPS J. 12(1), 87-97 (2010).
174. Fimognari C, Lenzi M, Hrelia P. Chemoprevention of cancer by isothiocyanates and anthocyanins: mechanisms of action and structure-activity relationship. Curr. Med. Chem. 15(5), 440-447 (2008).
175. Wilkinson JT, Morse MA, Kresty LA, Stoner GD. Effect of alkyl chain length on inhibition of N-nitrosomethylbenzylamine-induced esophageal tumorigenesis and DNA methylation by isothiocyanates. Carcinogenesis 16(5), 1011-1015 (1995).
176. Lu Q, Lin X, Feng J et al. Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J. Hematol. Oncol. 1, 6 (2008).
177. Beklemisheva AA, Fang Y, Feng J, Ma X, Dai W, Chiao JW. Epigenetic mechanism of growth inhibition induced by phenylhexyl isothiocyanate in prostate cancer cells. Anticancer Res. 26(2A), 1225-1230 (2006).
178. Ma X, Fang Y, Beklemisheva A et al. Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells. Int. J. Oncol. 28, 1287-1293 (2006).
179. Wang LG, Beklemisheva A, Liu XM, Ferrari AC, Feng J, Chiao JW. Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer. Mol. Carcinogenesis 46(1), 24-31 (2007).
180. Higdon JV, Delage B, Williams DE, Dashwood RH. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharm. Res. 55(3), 224-236 (2007).
181. Pledgie-Tracy A, Sobolewski MD, Davidson NE. Sulforaphane induces cell
182. Keum Y-S, Khor TO, Lin W et al. Pharmacokinetics and pharmacodynamics of broccoli sprouts on the suppression of prostate cancer in transgenic adenocarcinoma of mouse prostate (TRAMP) mice: implication of induction of Nrf2, HO-1 and apoptosis and the suppression of Akt-dependent kinase pathway. Pharm. Res. 26(10), 2324-2331 (2009).
183. Bhamre S, Sahoo D, Tibshirani R, Dill DL, Brooks JD. Temporal changes in gene expression induced by sulforaphane in human prostate cancer cells. Prostate 69(2), 181-190 (2009).
184. Telang U, Brazeau DA, Morris ME. Comparison of the effects of phenethyl isothiocyanate and sulforaphane on gene expression in breast cancer and normal mammary epithelial cells. Exp. Biol. Med. 234(3), 287-295 (2009).
185. Dashwood RH, Ho E. Dietary agents as histone deacetylase inhibitors: sulforaphane and structurally related isothiocyanates. Nutr. Rev. 66, S36-S38 (2008).
186. Myzak MC, Tong P, Dashwood W-M, Dashwood RH, Ho E. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp. Biol. Med. 232(2), 227-234 (2007).
187. Lemire M, Fillion M, Barbosa F Jr, Guimaraes JR, Mergler D. Elevated levels of selenium in the typical diet of Amazonian riverside populations. Sci. Total Environ. 408(19), 4076-4084 (2010).
188. Fischer JL, Lancia JK, Mathur A, Smith ML. Selenium protection from DNA damage involves a Ref1/p53/Brca1 protein complex. Anticancer Res. 26(2A), 899-904 (2006).
189. Combs GF Jr, Clark LC, Turnbull BW. An analysis of cancer prevention by selenium. Biofactors 14(1), 153-159 (2001).
190. Redman C, Scott JA, Baines AT et al. Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett. 125(1-2), 103-110 (1998).
191. Xiang N, Zhao R, Song G, Zhong W. Selenite reactivates silenced genes by modifying DNA methylation and histones in prostate cancer cells.Carcinogenesis 29(11), 2175-2181 (2008).
192. Zhuo P, Diamond AM. Molecular mechanisms by which selenoproteins affect cancer risk and progression. Biochim. Biophys. Acta (BBA) 1790(11), 1546-1554 (2009).
193. Clark LC, Combs GF, Turnbull BW et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 276(24), 1957-1963 (1996).
194. Hirsch FR, Lippman SM. Advances in the biology of lung cancer chemoprevention. J. Clin. Oncol. 23(14), 3186-3197 (2005).
195. Uthus E, Ross S, Davis C. Differential effects of dietary selenium (Se) and folate on methyl metabolism in liver and colon of rats. Biol. Trace Element Res. 109(3), 201-214 (2006).
196. Davis CD, Uthus EO. Dietary folate and selenium affect dimethylhydrazine-induced aberrant crypt formation, global DNA methylation and one-carbon metabolism in rats. J. Nutr. 133(9), 2907-2914 (2003).
197. Davis CD, Uthus EO, Finley JW. Dietary selenium and arsenic affect DNA methylation in vitro in Caco-2 cells and in vivo in rat liver and colon. J. Nutr. 130(12), 2903-2909 (2000).
198. Uthus EO, Yokoi K, Davis CD. Selenium deficiency in Fisher-344 rats decreases plasma and tissue homocysteine concentrations and alters plasma homocysteine and cysteine redox status. J. Nutr. 132(6), 1122-1128 (2002).
199. Alpers DH. Garlic and its potential for prevention of colorectal cancer and other conditions. Curr. Opin. Gastroenterol. 25(2), 116-121 (2009).
200. Nian H, Delage B, Ho E, Dashwood RH. Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds. Environ. Mol. Mutagen. 50(3), 213-221 (2009).
201. Nian H, Delage B, Pinto JT, Dashwood RH. Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter. Carcinogenesis 29(9), 1816-1824 (2008).
202. Lea MA, Randolph VM, Lee JE, Desbordes C. Induction of histone acetylation in mouse erythroleukemia cells by some organosulfur compounds including allyl isothiocyanate. Int. J. Cancer 92(6), 784-789 (2001).
203. Lea MA, Ibeh C, Han L, Desbordes C. Inhibition of growth and induction of differentiation markers by polyphenolic molecules and histone deacetylase inhibitors in colon cancer cells. Anticancer Res. 30(2), 311-318 (2010).
204. Cole BF, Baron JA, Sandler RS et al. Folic acid for the prevention of colorectal adenomas. JAMA 297(21), 2351-2359 (2007).
205. Mai A, Massa S, Rotili D et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med. Res. Rev. 25(3), 261-309 (2005).
206. Kim Y-I. Folate and colorectal cancer: an evidence-based critical review. Mol. Nutr. Food Res. 51(3), 267-292 (2007).
207. Duthie S. Folate and cancer: how DNA damage, repair and methylation impact on colon carcinogenesis. J. Inherited Metab. Dis. 34(1), 101-109 (2011).
208. Yang Q, Bostick RM, Friedman JM, Flanders WD. Serum folate and cancer mortality among U.S. adults: findings from the third national health and nutritional examination survey linked mortality file. Cancer Epidemiol. Biomark. Prev. 18(5), 1439-1447 (2009).
209. Lu R, Wang X, Sun D-F et al. Folic acid and sodium butyrate prevent tumorigenesis in a mouse model of colorectal cancer. Epigenetics 3(6), 330-335 (2008).
210. Marsit CJ, Mcclean MD, Furniss CS, Kelsey KT. Epigenetic inactivation of the SFRP genes is associated with drinking, smoking and HPV in head and neck squamous cell carcinoma. Int. J. Cancer 119(8), 1761-1766 (2006).
211. Van Engeland M, Weijenberg MP, Roemen GM et al. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: The Netherlands cohort study on diet and cancer. Cancer Res. 63(12), 3133-3137 (2003).
212. Giovannucci E, Rimm EB, Ascherio A, Stampfer MJ, Colditz GA, Willett WC. Alcohol, low-methionine-low-folate diets, and risk of colon cancer in men. J. Natl Cancer Inst. 87(4), 265-273 (1995).
213. Puri SK, Si L, Fan C-Y, Hanna E. Aberrant promoter hypermethylation of multiple genes in head and neck squamous cell carcinoma. Am. J. Otolaryngol. 26(1), 12-17 (2005).
214. Lee WJ, Zhu BT. Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis 27(2), 269-277 (2006).
215. Davis CD, Milner JA. Biomarkers for diet and cancer prevention research: potentials and challenges. Acta Pharmacol. Sin. 28(9), 1262-1273 (2007).
216. Sun Y, Jiang X, Chen S, Price BD. Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation. FEBS Lett. 580(18), 4353-4356 (2006).
217. Eliseeva ED, Valkov V, Jung M, Jung MO. Characterization of novel inhibitors of histone acetyltransferases. Mol. Cancer Ther. 6(9), 2391-2398 (2007).
218. Davis CD, Milner J. Frontiers in nutrigenomics, proteomics, metabolomics and cancer prevention. Mutat. Res. 551(1-2), 51-64 (2004).
219. Davis CD, Hord NG. Nutritional 'omics' technologies for elucidating the role(s) of bioactive food components in colon cancer prevention. J. Nutr. 135(11), 2694-2697 (2005).
220. Gallou-Kabani C, Vigé A, Gross M-S, Junien C. Nutri-epigenomics: lifelong remodelling of our epigenomes by nutritional and metabolic factors and beyond. Clin. Chem. Lab. Med. 45(3), 321-327 (2007).